CagriSema is a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a glucagon-like peptide-1 receptor agonist.

The Food and Drug Administration (FDA) has approved Alyftrek ™ (vanzacaftor/tezacaftor/deutivacaftor) for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one ...

The Food and Drug Administration (FDA) has approved Ryoncil ® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft vs host disease (SR-aGvHD) in pediatric patients 2 months of age ...

The Food and Drug Administration (FDA) has approved Zepbound ® (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity.

Black mothers are faced with a disproportionate number of barriers to breastfeeding compared to other racial and ethnic groups.

Black mothers are faced with a disproportionate number of barriers to breastfeeding compared to other racial and ethnic groups.

Patients with a sepsis alert were more likely to have serum lactate tested and intravenous fluid ordered, reducing in-hospital mortality rates. HealthDay News — Electronic sepsis screening among ...

As long as a drug shortage is declared, compounding pharmacies are still eligible to produce their own versions of Zepbound/Mounjaro. HealthDay News — The US Food and Drug Administration re ...

Credit: Celltrion Steqeyma, formerly known as CT-P43, is a human interleukin-12 and -23 antagonist. According to Celltrion, Steqeyma is expected to be available in February 2025. The Food and Drug ...

Vitamin D supplementation, with or without calcium, offers no benefit for preventing falls or fractures in community-dwelling seniors and may increase risk of kidney stones. HealthDay News — The ...